Currently, our country has carried out six batches of bulk procurement of drugs, involving an amount accounting for 30% of the total annual drug procurement by public medical institutions. In 2021, a special procurement of insulin was carried out, and for the first time the centralized procurement was expanded from chemical drugs. to the field of biopharmaceuticals.
Chen Jinfu, Deputy Director of the National Medical Security Administration: The first six batches of centralized procurement of drugs dropped by an average of 53%, cardiac stents dropped by an average of 93%, and artificial hip and knee joints dropped by an average of 82%. Judging from the cumulative results of the three-year reform, the state organized centralized procurement to save more than 260 billion yuan, and the overall drug price level showed a steady but declining trend.
my country will comprehensively promote the speed and expansion of centralized procurement. By the end of 2022, the total number of national and provincial centralized procurement drugs will reach more than 350 in each province, and the centralized procurement varieties of high-value medical consumables will reach more than 5, making centralized procurement the basic mode of procurement for public medical institutions. Chen Jinfu said that the centralized purchasing of high-value medical consumables focuses on orthopedic consumables, pharmaceutical balloons, dental implants and other varieties.
Chen Jinfu: Dental implants are an important treatment method for repairing missing teeth, and there is also great social demand. The plan has been deployed since the beginning of last year, and now the plan is basically mature. In the first half of this year, we strive to launch a local centralized procurement alliance reform.